Dataset Information

Clinical performance of Ambu AuraGain^TM versus i-gel^TM in anesthetized children: a prospective, randomized controlled trial.

ABSTRACT:

Background

Ambu AuraGain and i-gel have different characteristics in design each other. However, few reports evaluate which device has more benefits for ventilation in children undergoing paralyzed general anesthesia. This prospective, randomized controlled trial compared the clinical performance AuraGain and i-gel in anesthetized children.

Methods

Children aged between 1 month and 7 years undergoing elective surgery were randomly assigned to the AuraGain and i-gel groups. The primary outcome was initial oropharyngeal leak pressure (OLP). Secondary outcomes were OLP at 10 min post-insertion, first-attempt and total insertion success rates, number of attempts and ease of gastric suction catheter placement, peak inspiratory pressure, fiberoptic bronchoscopic view score, ventilation quality, requirement of additional manipulation post-insertion, and complications.

Results

Data of 93 patients were analyzed. The initial OLPs of the AuraGain and i-gel were 27.5 ± 7.7 and 25.0 ± 8.0 cmH₂O, respectively (P = 0.130). The OLP was significantly increased 10 min post-insertion in both groups. The initial success rates of the AuraGain and i-gel insertion were comparable. Suction catheter placement via the gastric port was easier (P = 0.018) and fiberoptic bronchoscopic view was better with the AuraGain (P < 0.001). The i-gel required additional manipulations post-insertion (P = 0.038). The incidence of complications during the emergence period was 10.8% for the i-gel^TM and 2.2% for the AuraGain (P = 0.1).

Conclusions

OLP is comparable between AuraGain and i-gel. The AuraGain would be more favorable than the i-gel^TM for use in pediatric patients under general anesthesia considering other outcomes.

SUBMITTER: Lee JH

PROVIDER: S-EPMC7713828 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Clinical performance of Ambu AuraGain<sup>TM</sup> versus i-gel<sup>TM</sup> in anesthetized children: a prospective, randomized controlled trial.

Lee Ji-Hyun JH Nam Seungpyo S Jang Young-Eun YE Kim Eun-Hee EH Kim Hee-Soo HS Kim Jin-Tae JT

Anesthesia and pain medicine 20200429 2

<h4>Background</h4>Ambu AuraGain and i-gel have different characteristics in design each other. However, few reports evaluate which device has more benefits for ventilation in children undergoing paralyzed general anesthesia. This prospective, randomized controlled trial compared the clinical performance AuraGain and i-gel in anesthetized children.<h4>Methods</h4>Children aged between 1 month and 7 years undergoing elective surgery were randomly assigned to the AuraGain and i-gel groups. The pri ...[more]

PMID: 33329810

Similar Datasets

Project description:Seven percent of UK households are estimated to own both a cat and a dog, despite a popular view that the two do not live well together. This is the first study to evaluate the effects of pheromone products Feliway FriendsTM and AdaptilTM on cat-dog interactions, in homes where owners perceived the potential for improvement in the relationship between their cat and dog. A blinded parallel randomized trial design over a 6-week period was used to evaluate the effect of each of the two products, with 17 participants in each group completing the trial. Owners reported weekly on the frequency of 10 specific undesirable interactions and seven specific desirable interactions. Total undesirable and desirable interaction scores both showed significant linear contrasts over time (undesirable score decreased; desirable score increased). Undesirable interaction scores were significantly lower (with a very large effect size) during treatment compared with baseline. There were no significant differences between the two pheromone products in relation to these outcome measures. AdaptilTM and Feliway FriendsTM were both associated with a significant decrease in: dog chasing cat/cat runs away; cat hiding from dog; cat/dog staring at the other; and dog barking at cat. With AdaptilTM a significant increase was also seen in: friendly greeting and times spent relaxed in the same room. From baseline (Week 2) to the end of the study (Week 6) there was a significant improvement in owners' perception of dog relaxation in those participants who received AdaptilTM and of cat relaxation in those participants who received Feliway FriendsTM. Similarity in the core chemical structure of the appeasing pheromones might explain the main effects, whilst different species-specific additions may explain the product-appropriate species-specific increases in relaxation scores. Specific behavioral improvements seen with AdaptilTM may reflect a greater calming of dogs in this group, reducing their interest in seeking interaction with cats in the same home and the tension in the cat as a result. In conclusion, both products appear to improve the cat-dog relationship and it would be beneficial to further study their use in combination and against placebo. If selecting one product AdaptilTM may be preferable, unless there is a particular need to increase the cat's relaxation.

Project description:BackgroundLittle is known about knee mechanics and muscle control after augmented ACL repair. Our aim was to compare knee biomechanics and leg muscle activity during walking between the legs of patients 2 years after InternalBraceTM-augmented anterior cruciate ligament repair (ACL-IB) and between patients after ACL-IB and ACL reconstruction (ACL-R), and controls.MethodsTwenty-nine ACL-IB, 27 sex- and age-matched ACL-R (hamstring tendon autograft) and 29 matched controls completed an instrumented gait analysis. Knee joint angles, moments, power, and leg muscle activity were compared between the involved and uninvolved leg in ACL-IB (paired t-tests), and between the involved legs in ACL patients and the non-dominant leg in controls (analysis of variance and posthoc Bonferroni tests) using statistical parametric mapping (SPM, P < 0.05). Means and 95% confidence intervals (CI) of differences in discrete parameters (DP; i.e., maximum/minimum) were calculated.ResultsSignificant differences were observed in ACL-IB only in minimum knee flexion angle (DP: 2.4°, CI [-4.4;-0.5]; involved > uninvolved) and maximum knee flexion moment during stance (-0.07Nm/kg, CI [-0.13;-0.00]; involved < uninvolved), and differences between ACL-IB and ACL-R only in maximum knee flexion during swing (DP: 3.6°, CI [0.5;7.0]; ACL-IB > ACL-R). Compared to controls, ACL-IB (SPM: 0-3%GC, P = 0.015; 98-100%, P = 0.016; DP: -6.3 mm, CI [-11.7;-0.8]) and ACL-R (DP: -6.0 mm, CI [-11.4;-0.2]) had lower (maximum) anterior tibia position around heel strike. ACL-R also had lower maximum knee extension moment (DP: -0.13Nm/kg, CI [-0.23;-0.02]) and internal knee rotation moment (SPM: 34-41%GC, P < 0.001; DP: -0.03Nm/kg, CI [-0.06;-0.00]) during stance, and greater maximum semitendinosus activity before heel strike (DP: 11.2%maximum voluntary contraction, CI [0.1;21.3]) than controls.ConclusionOur results suggest comparable ambulatory knee function 2 years after ACL-IB and ACL-R, with ACL-IB showing only small differences between legs. However, the differences between both ACL groups and controls suggest that function in the involved leg is not fully recovered and that ACL tear is not only a mechanical disruption but also affects the sensorimotor integrity, which may not be restored after surgery. The trend toward fewer abnormalities in knee moments and semitendinosus muscle function during walking after ACL-IB warrants further investigation and may underscore the importance of preserving the hamstring muscles as ACL agonists.Level of evidenceLevel III, case-control study.Trial registrationclinicaltrials.gov, NCT04429165 (12/06/2020).

Dataset Information

Clinical performance of Ambu AuraGain^TM versus i-gel^TM in anesthetized children: a prospective, randomized controlled trial.

Background

Methods

Results

Conclusions

Publications

Clinical performance of Ambu AuraGain<sup>TM</sup> versus i-gel<sup>TM</sup> in anesthetized children: a prospective, randomized controlled trial.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Clinical performance of Ambu AuraGainTM versus i-gelTM in anesthetized children: a prospective, randomized controlled trial.

Background

Methods

Results

Conclusions

Publications

Clinical performance of Ambu AuraGain<sup>TM</sup> versus i-gel<sup>TM</sup> in anesthetized children: a prospective, randomized controlled trial.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Clinical performance of Ambu AuraGain^TM versus i-gel^TM in anesthetized children: a prospective, randomized controlled trial.